Atara Biotherapeutics, Inc.

NasdaqGS:ATRA Stock Report

Market Cap: US$34.3m

Atara Biotherapeutics Future Growth

Future criteria checks 0/6

Atara Biotherapeutics's revenue is forecast to decline at 14.9% per annum while its annual earnings are expected to grow at 46.6% per year. EPS is expected to grow by 51.5% per annum.

Key information

46.6%

Earnings growth rate

51.5%

EPS growth rate

Biotechs earnings growth27.7%
Revenue growth rate-14.9%
Future return on equityn/a
Analyst coverage

Low

Last updated01 Apr 2025

Recent future growth updates

Recent updates

Lacklustre Performance Is Driving Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) 27% Price Drop

Mar 07
Lacklustre Performance Is Driving Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) 27% Price Drop

Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues

Jan 21

Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Boosted 25% But Its Business Prospects Need A Lift Too

Jan 16
Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Boosted 25% But Its Business Prospects Need A Lift Too

Is Atara Biotherapeutics (NASDAQ:ATRA) In A Good Position To Deliver On Growth Plans?

Jan 07
Is Atara Biotherapeutics (NASDAQ:ATRA) In A Good Position To Deliver On Growth Plans?

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Nov 06
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Sep 06
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry

Jul 21
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry

Atara Biotherapeutics: An Underestimated Contender In Autoimmune Diseases CAR-T Cell Therapy

Jul 03

New Forecasts: Here's What Analysts Think The Future Holds For Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

May 14
New Forecasts: Here's What Analysts Think The Future Holds For Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Revenues Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 26% Dive

May 11
Revenues Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 26% Dive

Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway

Feb 06

Here's Why Atara Biotherapeutics (NASDAQ:ATRA) Must Use Its Cash Wisely

Oct 17
Here's Why Atara Biotherapeutics (NASDAQ:ATRA) Must Use Its Cash Wisely

Earnings Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 32% Dive

May 18
Earnings Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 32% Dive

Earnings and Revenue Growth Forecasts

NasdaqGS:ATRA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202724-41N/AN/A3
12/31/202632-36N/A-393
12/31/202542-53N/A-444
12/31/2024129-85-69-69N/A
9/30/2024100-133-95-95N/A
6/30/202462-181-142-142N/A
3/31/202435-233-185-184N/A
12/31/20239-276-194-193N/A
9/30/20235-290-201-199N/A
6/30/20237-305-214-213N/A
3/31/202357-215-226-224N/A
12/31/202264-228-275-270N/A
9/30/202271-247-254-248N/A
6/30/202272-248-252-242N/A
3/31/202224-350-250-239N/A
12/31/202120-340-231-221N/A
9/30/202113-328-199-190N/A
6/30/20217-318-190-184N/A
3/31/20214-311-185-179N/A
12/31/2020N/A-307-185-181N/A
9/30/2020N/A-304-242-235N/A
6/30/2020N/A-301-242-235N/A
3/31/2020N/A-298-239-232N/A
12/31/2019N/A-291-241-236N/A
9/30/2019N/A-292-242-234N/A
6/30/2019N/A-279-241-230N/A
3/31/2019N/A-256-232-215N/A
12/31/2018N/A-231-216-180N/A
9/30/2018N/A-186N/A-147N/A
6/30/2018N/A-159N/A-119N/A
3/31/2018N/A-135N/A-100N/A
12/31/2017N/A-119N/A-88N/A
9/30/2017N/A-102N/A-84N/A
6/30/2017N/A-97N/A-79N/A
3/31/2017N/A-88N/A-70N/A
12/31/2016N/A-79N/A-60N/A
9/30/2016N/A-82N/A-50N/A
6/30/2016N/A-69N/A-48N/A
3/31/2016N/A-65N/A-43N/A
12/31/2015N/A-57N/A-37N/A
9/30/2015N/A-46N/A-31N/A
6/30/2015N/A-41N/A-22N/A
3/31/2015N/A-30N/A-20N/A
12/31/2014N/A-28N/A-17N/A
9/30/2014N/A-21N/A-14N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ATRA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ATRA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ATRA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ATRA's revenue is expected to decline over the next 3 years (-14.9% per year).

High Growth Revenue: ATRA's revenue is forecast to decline over the next 3 years (-14.9% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ATRA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/15 19:14
End of Day Share Price 2025/04/15 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Atara Biotherapeutics, Inc. is covered by 15 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John NewmanCanaccord Genuity
Yigal NochomovitzCitigroup Inc
Michael KingCitizens JMP Securities, LLC